ExLibris header image
SFX Logo
Title: CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
Source:

Blood [0006-4971] Hu, Shimin yr:2013


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Horn, H. "MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma." Blood 121.12 (2013): 2253-2263. Link to SFX for this item
2. Heidi Nyman, Mats Jerkeman, Marja-Liisa Karjalainen-Lindsberg, Alison H. Banham, Gunilla Enblad, Sirpa Leppä;, H. "Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas." European journal of haematology (2009): 364-72. Link to Full Text for this item Link to SFX for this item
3. Chang, H. "Surgical site spread of skeletal diffuse large B-cell lymphoma." Journal of clinical oncology 31.9 (2013): 141-3. Link to SFX for this item
4. Young, Y. "Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP consortiu." Leukemia 26.9 (2012): 2103-2113. Link to Full Text for this item Link to SFX for this item
5. Rigby, J. "Can physical trauma cause breast cancer?" European journal of cancer prevention 11.3 (2002): 307-311. Link to SFX for this item
6. Barista, I. "Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab." Cancer 118.17 (2011): 4173-83. Link to Full Text for this item Link to SFX for this item
7. Gray, R. "Incremental value in outcome prediction with gene-expression based signatures in diffuse large B-cell lymphoma." Blood (2012): 156-158. Link to SFX for this item
8. Mller, Michael B. "High Levels of Nuclear MYC Protein Predict the Presence of MYC Rearrangement in Diffuse Large B-cell Lymphoma." The American journal of surgical pathology 36.4 (2012): 612-619. Link to SFX for this item
9. Picozzi, V J. "Treatment of lymphoblastic lymphoma in adults." Journal of clinical oncology 4.11 (1986): 1628-37. Link to SFX for this item
10. Philippo, M H M. "Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma." Blood 92.9 (1998): 3152-62. Link to SFX for this item
11. Hallack Neto, D A F E. "Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT." Bone marrow transplantation (2009): 323-325. Link to Full Text for this item Link to SFX for this item
12. Tanaka, A. "Th2 and regulatory immune reactions contributes to IgG4 production and the initiation of Mikulicz's disease." Arthritis & rheumatism 64.1 (2011): 254-263. Link to Full Text for this item Link to SFX for this item
13. Ninan, Mary J. "Prognostication of diffuse large B-cell lymphoma in the rituximab era." Leukemia & lymphoma 52.3 (2011): 360-373. Link to SFX for this item
14. Nyman, S. "Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP." Modern Pathology 22.8 (2009): 1094-101. Link to Full Text for this item Link to SFX for this item
15. Malloy, Rachel L L. "An automated communication system in a Contact Registry for persons with rare diseases: tools for retaining potential clinical research participants." AMIA ... Annual Symposium proceedings (2007): 1094-1094. Link to Full Text for this item Link to SFX for this item
16. Gurcan, A Razzaque M. "A review of the current use of rituximab in autoimmune diseases." International immunopharmacology 9.1 (2008): 10-25. Link to SFX for this item
17. Stewart, D. E., T. "Attributions of cause and recurrence in long-term breast cancer survivors." Psycho-oncology 10.2 (2001): 179-83. Link to Full Text for this item Link to SFX for this item
18. Esteller, M. "Epigenetics in cancer." New England Journal of Medicine, The 358.11 (2008): 1148-1159. Link to SFX for this item
19. Sharma, S. "Epigenetics in Cancer." Carcinogenesis 31.1 (2009): 27-36. Link to SFX for this item
20. Lai, Y. "Survival analysis by penalized regression and matrix factorization." TheScientificWorldjournal 2013 (2013): 632030-632030. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.